FOR ORAL USE IN HORSES ONLY
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
DESCRIPTION: EQUIPHEN® PASTE (PHENYLBUTAZONE) is a synthetic, non-hormonal, anti-inflammatory, antipyretic compound useful in the management of inflammatory conditions. The apparent analgesic effect is probably related mainly to the anti-inflammatory properties of the compound.
Chemically, phenylbutazone is 4-butyl-1,2-diphenyl-3,5-pyrazolidine-dione. It is a pyrazolone derivative, entirely unrelated to the steroid hormones,
Molecular Weight 308.38
INDICATIONS: For relief of inflammatory conditions associated with the musculoskeletal system in horses.
DOSAGE AND ADMINISTRATION: Each increment of the plunger delivers 1 gram of phenylbutazone. Oral dose of 1 to 2 grams of phenylbutazone per 500 lbs. of body weight, but not to exceed 4 grams daily. Use a relatively high dose for the first 48 hours, then reduce gradually to a maintenance dose. Maintain lowest dose capable of producing desired clinical response.
Guidelines to Successful Therapy:
1) Use a relatively high dose for the first 48 hours, then reduce gradually to a maintenance dose. Maintain lowest dose capable of producing desired clinical response.
2) Response to EQUIPHEN® PASTE (PHENYLBUTAZONE) therapy is prompt, usually occurring within 24 hours. If no significant clinical response is evident after 5 days, re-evaluate diagnosis and therapeutic approach.
3) When administering EQUIPHEN® PASTE (PHENYLBUTAZONE) the oral cavity should be empty. Deposit paste on back of tongue by depressing plunger that has been previously set to deliver the correct dose.
4) Many chronic conditions will respond to EQUIPHEN® PASTE (PHENYLBUTAZONE) therapy, but discontinuance of treatment may result in recurrence of symptoms.
CONTRAINDICATIONS: Use with caution in patients who have a history of drug allergy.
WARNING: Do not use in horses intended for human consumption. KEEP THIS AND ALL MEDICATION OUT OF THE REACH OF CHILDREN.
PRECAUTIONS: Stop medication at the first sign of gastrointestinal upset, jaundice, or blood dyscrasia. Authenticated cases of agranulocytosis associated with the drug have occurred in man; fatal reactions, although rare, have been reported in dogs after long-term therapy. To guard against this possibility, conduct routine blood counts at weekly intervals during the early phase of therapy and at intervals of two weeks thereafter. Any significant fall in the total white count, relative decrease in granulocytes, or black or tarry stools, should be regarded as a signal for immediate cessation of therapy and institution of appropriate counter measures. In the treatment of inflammatory conditions associated with infections, specific anti-infective therapy is required.
Store at controlled room temperature of 15°-30°C (59°-86°F) (See USP).
HOW SUPPLIED: Syringes containing 12 grams of EQUIPHEN® PASTE (PHENYLBUTAZONE). APPLE FLAVORED.
12 grams of Phenylbutazone
Net Wt. 60 grams
Manufactured for: LUITPOLD PHARMACEUTICALS, INC., Animal Health Division, Shirley, NY 11967
NADA 140-958, Approved by FDA
NAC No.: 10390034